142 related articles for article (PubMed ID: 12153179)
21. Tumor cells fight back to beat immune system.
Williams N
Science; 1996 Nov; 274(5291):1302. PubMed ID: 8966600
[No Abstract] [Full Text] [Related]
22. Basic biology of autoimmune phenomena in chronic lymphocytic leukemia.
Pritsch O; Maloum K; Dighiero G
Semin Oncol; 1998 Feb; 25(1):34-41. PubMed ID: 9482525
[TBL] [Abstract][Full Text] [Related]
23. miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL.
Berg V; Rusch M; Vartak N; Jüngst C; Schauss A; Waldmann H; Hedberg C; Pallasch CP; Bastiaens PI; Hallek M; Wendtner CM; Frenzel LP
Blood; 2015 May; 125(19):2948-57. PubMed ID: 25670628
[TBL] [Abstract][Full Text] [Related]
24. [Impaired CD95-(Fas,APO-1-)apoptosis regulation is a progression factor in early MALT-type lymphoma genesis].
Seeberger H; Knörr C; Müller-Hermelink HK; Greiner A
Med Klin (Munich); 2001 Jan; 96(1):9-14. PubMed ID: 11210492
[TBL] [Abstract][Full Text] [Related]
25. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.
Panayiotidis P; Ganeshaguru K; Foroni L; Hoffbrand AV
Leukemia; 1995 Jul; 9(7):1227-32. PubMed ID: 7543175
[TBL] [Abstract][Full Text] [Related]
26. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
Hanna BS; Öztürk S; Seiffert M
Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
[TBL] [Abstract][Full Text] [Related]
27. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications.
Strand S; Galle PR
Mol Med Today; 1998 Feb; 4(2):63-8. PubMed ID: 9547792
[TBL] [Abstract][Full Text] [Related]
28. Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms.
Tsuruda K; Yamada Y; Hirakata Y; Sugahara K; Maeda T; Atogami S; Tomonaga M; Kamihira S
Leuk Res; 1999 Feb; 23(2):159-66. PubMed ID: 10071131
[TBL] [Abstract][Full Text] [Related]
29. Fas receptor (CD95)-mediated apoptosis in leukemic cells.
Komada Y; Sakurai M
Leuk Lymphoma; 1997 Mar; 25(1-2):9-21. PubMed ID: 9130610
[TBL] [Abstract][Full Text] [Related]
30. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L).
Gutierrez-Steil C; Wrone-Smith T; Sun X; Krueger JG; Coven T; Nickoloff BJ
J Clin Invest; 1998 Jan; 101(1):33-9. PubMed ID: 9421463
[TBL] [Abstract][Full Text] [Related]
31. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes.
Fais F; Morabito F; Stelitano C; Callea V; Zanardi S; Scudeletti M; Varese P; Ciccone E; Grossi CE
Int J Cancer; 2004 Apr; 109(3):402-11. PubMed ID: 14961579
[TBL] [Abstract][Full Text] [Related]
32. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
[TBL] [Abstract][Full Text] [Related]
33. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand.
Müller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH
Eur J Immunol; 1995 Oct; 25(10):2996-9. PubMed ID: 7589104
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway.
Porakishvili N; Kardava L; Jewell AP; Yong K; Glennie MJ; Akbar A; Lydyard PM
Haematologica; 2004 Apr; 89(4):435-43. PubMed ID: 15075077
[TBL] [Abstract][Full Text] [Related]
35. Regulation of B-CLL apoptosis through membrane receptors and Bcl-2 family proteins.
Osorio LM; Jondal M; Aguilar-Santelises M
Leuk Lymphoma; 1998 Jul; 30(3-4):247-56. PubMed ID: 9713957
[TBL] [Abstract][Full Text] [Related]
36. Mycobacterium tuberculosis exploits the CD95/CD95 ligand system of gammadelta T cells to cause apoptosis.
Manfredi AA; Heltai S; Rovere P; Sciorati C; Paolucci C; Galati G; Rugarli C; Vaiani R; Clementi E; Ferrarini M
Eur J Immunol; 1998 Jun; 28(6):1798-806. PubMed ID: 9645360
[TBL] [Abstract][Full Text] [Related]
37. Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis.
Romano C; De Fanis U; Sellitto A; Chiurazzi F; Guastafierro S; Giunta R; Tirelli A; Rotoli B; Lucivero G
Immunol Lett; 2005 Feb; 97(1):131-9. PubMed ID: 15626485
[TBL] [Abstract][Full Text] [Related]
38. Cell death induced by the Fas/Fas ligand pathway and its role in pathology.
Waring P; Müllbacher A
Immunol Cell Biol; 1999 Aug; 77(4):312-7. PubMed ID: 10457197
[TBL] [Abstract][Full Text] [Related]
39. Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death.
Stohl W; Xu D; Starling GC; Casali P; Kiener PA
Cell Immunol; 2000 Jul; 203(1):1-11. PubMed ID: 10915556
[TBL] [Abstract][Full Text] [Related]
40. Tumor expression of Fas ligand (CD95L) and the consequences.
Walker PR; Saas P; Dietrich PY
Curr Opin Immunol; 1998 Oct; 10(5):564-72. PubMed ID: 9794830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
